In CTD-PAH, treatment-naïve patient baseline levels of placental growth factor (PlGF), sVEGFR-1, TNF-α, and VEGF-D were increased and could differentiate between healthy controls/IPAH and CTD-PAH. This evidence concerns the gene PGF and pulmonary arterial hypertension.